Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. - Wikidata - awgldk - TriplyDB

Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

http://www.wikidata.org/entity/Q54735427

about

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells Computational medicine: translating models to clinical care Cancer systems biology: a network modeling perspective New types of experimental data shape the use of enzyme kinetics for dynamic network modeling Targeting of erbB3 receptor to overcome resistance in cancer treatment Regulation of ERBB3/HER3 signaling in cancer In silico model-based inference: a contemporary approach for hypothesis testing in network biology Systems biology approaches for advancing the discovery of effective drug combinations Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.ErbB2 signaling at the crossing between heart failure and cancer Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data Functional Module Connectivity Map (FMCM): a framework for searching repurposed drug compounds for systems treatment of cancer and an application to colorectal adenocarcinoma Semantically linking in silico cancer models Toward an integrated software platform for systems pharmacology A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death Tailored parameter optimization methods for ordinary differential equation models with steady-state constraints An engineering design approach to systems biology.Models of signalling networks - what cell biologists can gain from them and give to them Systems analysis of small signaling modules relevant to eight human diseases Using partial least squares regression to analyze cellular response data.S100A4 and its role in metastasis – computational integration of data on biological networks.Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins.A simple knowledge-based mining method for exploring hidden key molecules in a human biomolecular network.Antibody Therapies in Cancer.Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3 ODE constrained mixture modelling: a method for unraveling subpopulation structures and dynamics Network systems biology for drug discovery.Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells Combining theoretical analysis and experimental data generation reveals IRF9 as a crucial factor for accelerating interferon α-induced early antiviral signalling.An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules.Proteogenomic convergence for understanding cancer pathways and networks.Receptor tyrosine kinase coactivation networks in cancer Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).Data-driven modelling of receptor tyrosine kinase signalling networks quantifies receptor-specific potencies of PI3K- and Ras-dependent ERK activation ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells.Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in EGFR addicted cancers.Monoclonal antibodies: versatile platforms for cancer immunotherapy.

P2860

Q24302462-78EE68DF-E673-4B04-96CB-ABF3B1531680 Q24594842-60C28FF0-7AA2-4093-A7C0-D077EACA3A22 Q24650086-C46FF4CD-A15E-4DE2-836A-B60D50BFAC82 Q26823013-D9099590-6C82-49B0-A518-FB194B0B58E8 Q26864668-9C583B02-BEC3-4486-B4D2-4DF0C554A2CE Q27024334-6AA5E181-6FE9-4AE7-9BA1-1832242A9A8C Q27339341-B1D7D05A-B055-4D97-BDD4-99B870B7F007 Q27702922-5C15B857-8345-437B-8E41-74F8115648A3 Q27853182-DA114801-61A4-4EE8-8819-CED37C711F09 Q28075244-A46DA056-FA13-4205-A40D-3419D8E569DD Q28472011-818E6411-CADD-4360-9408-4B8A56775ACC Q28539182-135D0041-E153-4429-A7A5-4DBE0899D083 Q28650150-CD4F0370-958A-4250-B342-A43A70DFBCCF Q28650510-C8301835-E2B2-45B7-8D5D-4BC7CDDE8FEB Q28740749-FE8AA16B-3FE0-40AE-8CDD-E136CD6778EB Q28829341-FB0317BC-15B0-45BD-9D66-424C6917800F Q30252189-C8A9D8F5-E950-438B-B078-F8B54ECE6C49 Q30413382-322E8AF3-BB27-4368-8F72-8DE9D1C09653 Q30432924-CDA6312B-A4B2-4BB6-9114-ACAA92D765F0 Q30617646-89F2BA93-0A1A-40DB-8CF8-69F5281A8E12 Q30977149-B1646F8F-6DA1-4C79-8469-372A4C9EEF85 Q30997919-B6ABCA75-4204-42B7-90AE-EF248919DF30 Q31090650-D628307B-90A4-4E94-9B70-9D95543139E0 Q31104000-4D2EEACA-7438-4C86-8F3E-2C16EDD2EFC6 Q31129446-55321A8D-1CC3-4D8C-BE57-AA5EC5FA0BE4 Q31172585-EDBD99F9-D066-448D-9BA7-DBFFC1621733 Q33592795-DF92AAE3-86EB-4B3A-80DA-512652B31614 Q33691823-C20A6F64-367B-469F-B6D2-E87EC120B51E Q33724668-7E531587-CEE4-4562-9E0E-8E1E12F245F4 Q33733313-0CC37C8F-40E9-443A-9777-01105A0795C9 Q33772914-38A5FCE6-2FD6-4028-8B72-78D8F043105C Q33777866-C4B53B12-C40C-4984-AB65-1FE94E8D8138 Q33792433-4EAD1AF6-A851-4981-8505-6A825F9D5F73 Q33871842-383A6F47-8D08-405C-81DE-AF641AD39B6F Q33875560-165216CF-5467-41CB-B6AD-52B20EF83B53 Q33917876-4D48691F-D566-45F1-92BE-F50370F74CB8 Q34029480-4E115D43-9E91-4C70-85BA-8A9543328FCB Q34104165-A88052EB-79A4-433B-BDA1-E71450B8DC2D Q34110540-71ED27E9-F8F4-45DF-A31D-515043D01559 Q34111693-A7E84F15-05EC-4133-B173-F5330AE76566

P2860

Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

http://www.wikidata.org/entity/Q54735427

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Therapeutically targeting ErbB ...... f the ErbB receptor-PI3K axis.

@en

Therapeutically targeting ErbB ...... f the ErbB receptor-PI3K axis.

@nl

type

label

Therapeutically targeting ErbB ...... f the ErbB receptor-PI3K axis.

@en

Therapeutically targeting ErbB ...... f the ErbB receptor-PI3K axis.

@nl

prefLabel

Therapeutically targeting ErbB ...... f the ErbB receptor-PI3K axis.

@en

Therapeutically targeting ErbB ...... f the ErbB receptor-PI3K axis.

@nl

P1433

Q54735427-8600E0F1-9668-4EDA-810B-8FAF1627934B

P1476

Q54735427-E7102F35-E15F-49D8-BA44-7E496DB3D8BB

P2093

Q54735427-0AE13A89-B673-4F24-9185-769B75A234D2

Q54735427-1D0482B9-E0A3-4110-843E-0B0E5ED6C577

Q54735427-2EC67A6F-48CA-415E-BE96-86878010EACD

Q54735427-3A2DDEB3-33D9-41D7-901C-71869CE07427

Q54735427-438DB803-5BFB-4F37-9E99-771D69083450

Q54735427-77AB4BAC-693C-4F4E-AF01-89258441FE52

Q54735427-92096C26-D016-4DA9-9CE3-40BA05670206

Q54735427-9A3DDEF1-4770-4207-9778-190F2444974B

Q54735427-AD62DEA0-3C37-412D-9241-0CADED58F3DC

Q54735427-B01E880A-03CB-492F-871E-F20E9A082F27

P304

Q54735427-10F21BC8-70F8-4A68-8A9D-F4F9A1BD1CE3

P31

Q54735427-F6466957-48CA-4089-B2C4-E70384D99F58

P356

Q54735427-38F6B626-9C40-47DC-AA42-84830160FFE6

P433

Q54735427-D6060C4C-A21F-4C61-ADA7-328421999B8A

P478

Q54735427-D4818433-485B-4CA2-B927-047E86D6C9DC

P50

Q54735427-3EF6D237-6A08-4A56-B6F7-8D7352237114

P577

Q54735427-8AF9E8DD-3A0C-463F-99FC-0B37D0B16E3D

P5875

Q54735427-CA802FC6-5B63-48C8-99E1-BA51F4ADD95C

P698

Q54735427-2F888F1E-A03D-48A4-A746-DA9726009E7E

P356

SCISIGNAL.2000352

P1433

Science Signaling

P1476

Therapeutically targeting ErbB ...... of the ErbB receptor-PI3K axis

@en

P2093

Arthur J Kudla

http://www.w3.org/2001/XMLSchema#string

Ashish Kalra

http://www.w3.org/2001/XMLSchema#string

Birgit Schoeberl

http://www.w3.org/2001/XMLSchema#string

Brian D Harms

http://www.w3.org/2001/XMLSchema#string

Bryan Linggi

http://www.w3.org/2001/XMLSchema#string

Emily A Pace

http://www.w3.org/2001/XMLSchema#string

Jonathan B Fitzgerald

http://www.w3.org/2001/XMLSchema#string

Kip A West

http://www.w3.org/2001/XMLSchema#string

Lin Nie

http://www.w3.org/2001/XMLSchema#string

Magdalena Leszczyniecka

http://www.w3.org/2001/XMLSchema#string

P304

ra31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCISIGNAL.2000352

http://www.w3.org/2001/XMLSchema#string

P433

77

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26331801

http://www.w3.org/2001/XMLSchema#string

P698

19567914

http://www.w3.org/2001/XMLSchema#string